<DOC>
	<DOCNO>NCT00334594</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Radiation therapy use high-energy x-ray kill tumor cell . Giving radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This randomized phase II trial study well give pemetrexed disodium together cisplatin follow surgery without radiation therapy work treat patient malignant pleural mesothelioma .</brief_summary>
	<brief_title>Pemetrexed Disodium Cisplatin Followed Surgery With Without Radiation Therapy Treating Patients With Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate short-term outcome feasibility neoadjuvant therapy pemetrexed disodium cisplatin follow extrapleural pneumonectomy patient malignant pleural mesothelioma . - Evaluate long-term outcome feasibility postoperative hemithoracic radiotherapy patient R0 R1 resection . Secondary - Determine quality life patient . - Identify predictive prognostic marker patient . - Determine relapse-free progression-free survival overall survival patient . - Collect tissue blood patient . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , histology ( sarcomatous v epithelial mixed histology ) , nodal status ( N0-1 v N2 ) , extent disease ( T1-2 v T3 ) . - Part 1 ( neoadjuvant therapy surgery ) : Patients receive pemetrexed disodium IV 10 minute cisplatin IV 2 hour day 1 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Within 8 week completion neoadjuvant therapy , patient without progressive disease undergo extrapleural pneumonectomy . - Part 2 : Patients achieve R0 R1 resection proceed part 2 study treatment randomize 1 2 treatment arm . Patients R2 resection , disease progression , symptomatic deterioration treatment part 1 take study . - Arm I ( postoperative radiotherapy ) : Patients undergo radiotherapy . Quality life assess baseline 6 , 10 , 16 , 22 week randomization . - Arm II ( postoperative radiotherapy ) : Beginning within 10 week surgery , patient undergo radiotherapy hemithoracic region 5 day week approximately 5 week absence disease progression unacceptable toxicity . Quality life assess baseline 4 , 8 , 14 , 20 week initiation radiotherapy . Patients undergo blood tissue collection registration surgery laboratory biomarker analysis . After completion study treatment , patient follow periodically 5 year surgery . PROJECTED ACCRUAL : A total 155 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant pleural mesothelioma T13 , N02 , M0 disease accord International Mesothelioma Interest Group stag system No obvious invasion mediastinal structure CT scan ( e.g. , heart , aorta , spine , esophagus ) No obvious widespread chest wall invasion Resectable chest wall lesion allow PATIENT CHARACTERISTICS : WHO performance score 01 Fit neoadjuvant therapy , surgery , postoperative radiotherapy Creatinine clearance &gt; 60 mL/min Hemoglobin ≥ 10.0 g/dL WBC ≥ 3,500/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN Alkaline phosphatase ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment FEV_1 ≥ 40 % predict base spirometry lung perfusion scan , necessary No serious underlie medical condition would preclude study requirement ( e.g. , active autoimmune disease uncontrolled diabetes ) No know hypersensitivity pemetrexed disodium , cisplatin , platinumcontaining substance component use preparation drug No restrict power hearing ( especially upper frequency range ) No acute infection PRIOR CONCURRENT THERAPY : No prior chemotherapy No treatment another clinical trial within past 30 day No prior pleurectomy lung resection No prior radiotherapy low neck , thorax , upper abdomen No aspirin , cyclooxygenase2 inhibitor , nonsteroidal antiinflammatory agent 5 day prior , , 2 day pemetrexed disodium administration No concurrent experimental drug anticancer therapy No concurrent drug would contraindicate study drug No concurrent vaccination yellow fever</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
	<keyword>stage IA malignant mesothelioma</keyword>
	<keyword>stage IB malignant mesothelioma</keyword>
	<keyword>stage II malignant mesothelioma</keyword>
	<keyword>stage III malignant mesothelioma</keyword>
</DOC>